Bhardwaj Anju, Januzzi James L
Cardiology Division, Massachusetts General Hospital, 32 Fruit Street, Boston, MA 02114, USA.
Crit Pathw Cardiol. 2009 Dec;8(4):146-50. doi: 10.1097/HPC.0b013e3181c4a0c6.
Natriuretic peptides (B-type natriuretic peptide [BNP] and N-terminal pro-B-type natriuretic peptide [NT]-proBNP) have been proven to be strong diagnostic and prognostic tools in the assessment of acutely decompensated heart failure. The emergence of BNP/NT-proBNP testing as a standard of care in this setting has helped to reduce healthcare costs, and may decrease adverse clinical outcomes. The use of BNP and NT-proBNP to "guide" treatment of acutely destabilized heart failure has recently grown. We present an overview of the value of BNP/NT-proBNP in the context of acute heart failure management and therapy optimization, and present an algorithm for natriuretic peptide-guided treatment of acutely destabilized heart failure.
利钠肽(B型利钠肽[BNP]和N末端前B型利钠肽[NT]-proBNP)已被证明是评估急性失代偿性心力衰竭的强有力的诊断和预后工具。在这种情况下,BNP/NT-proBNP检测作为一种护理标准的出现有助于降低医疗成本,并可能减少不良临床结局。最近,BNP和NT-proBNP用于“指导”急性失代偿性心力衰竭治疗的情况有所增加。我们概述了BNP/NT-proBNP在急性心力衰竭管理和治疗优化中的价值,并提出了一种利钠肽指导的急性失代偿性心力衰竭治疗算法。